Xponance Inc. Has $876,000 Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Xponance Inc. increased its stake in Insmed Incorporated (NASDAQ:INSM) by 23.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,689 shares of the biopharmaceutical company’s stock after acquiring an additional 2,380 shares during the quarter. Xponance Inc.’s holdings in Insmed were worth $876,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Abel Hall LLC lifted its position in shares of Insmed by 4.7% in the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 151 shares during the period. Commerce Bank raised its stake in Insmed by 2.4% during the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 163 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares during the period. M&T Bank Corp boosted its position in Insmed by 5.6% during the fourth quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company’s stock valued at $217,000 after acquiring an additional 166 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Insmed by 5.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 183 shares during the period.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the sale, the insider now directly owns 102,766 shares in the company, valued at $6,773,307.06. The trade was a 3.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the transaction, the chief executive officer now owns 334,186 shares of the company’s stock, valued at approximately $27,079,091.58. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock valued at $42,992,528 in the last 90 days. 4.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

INSM has been the topic of several research analyst reports. Guggenheim restated a “buy” rating and set a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. UBS Group increased their price target on Insmed from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Morgan Stanley lifted their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Wells Fargo & Company increased their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Finally, Truist Financial upped their price objective on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a report on Friday, February 21st. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus price target of $94.00.

Insmed Trading Down 0.7 %

NASDAQ INSM opened at $79.38 on Tuesday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The business has a fifty day simple moving average of $77.64 and a 200 day simple moving average of $73.84. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91. The firm has a market capitalization of $14.37 billion, a P/E ratio of -14.20 and a beta of 1.28.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. On average, analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.